SecBot SecBot
8-K ·Filed May 12, 2026

CRIS

CURIS INC
BEARISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001108205-26-000059
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The company has no revenue stream and is burning ~$11.5M/quarter in operating expenses. With only $15M cash and a $22M market cap, dilution risk is extreme. Monitor for the Series B warrant trigger (5th CLL patient dosing) as a potential near-term catalyst, but the fundamental trajectory is deteriorating.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$10.00
T+0 close · May 12, 2026 · via day close
Latest settled
−14.00%
T+20 · $8.60
Vs SPY
−13.39%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · May 13 $10.00entry
  2. T+1 · 6mo ago +2.00%α +1.21% · $10.20
  3. T+5 · 6mo ago 0.00%α +0.14% · $10.00
  4. T+20 · 5mo ago −14.00%α −13.39% · $8.60
  5. T+60 · due 3mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Curis reported Q1 2026 results with zero revenue (post-Erivedge sale) and a net loss of $24.2M, significantly worse than the prior year's $10.6M loss. The company's cash runway extends into H2 2027 only if Series B warrants are exercised, and the stock has a $22M market cap with a history of poor post-earnings performance.

Key Financial Metrics

EPS
−$1.25
est −$0.19 · -557.9%
Revenue
$0.00
est $1.9M · -100.0% · -100.0% YoY
Rating
strong miss

Key Facts

  • Zero revenue in Q1 2026 vs $2.4M in Q1 2025 due to sale of Erivedge royalties
  • Net loss of $24.2M ($1.25/share) vs $10.6M ($1.25/share) in Q1 2025
  • Cash and cash equivalents of $15.0M as of March 31, 2026
  • Operating cash burn of $11.5M in Q1 2026 vs $10.2M in Q1 2025
  • Warrant liability of $1.9M from January 2026 PIPE financing
  • Shares outstanding increased to ~40M from ~12.9M at year-end 2025
  • Cash runway guidance extends into H2 2027 only with Series B warrant exercise
  • Prior earnings report (Q4 2025) showed net income of $19.4M from a one-time gain on asset sale

Financial Impact

Revenue collapsed to zero; net loss more than doubled to $24.2M; cash burn rate increased

revenuenet_losscash_burndilution

Risk Factors

  • Zero revenue going forward after Erivedge royalty sale
  • Cash runway only extends to H2 2027 with warrant exercise; without it, runway is much shorter
  • Massive dilution: shares outstanding tripled to ~40M from ~12.9M
  • No approved products; clinical-stage pipeline with binary outcomes
  • Nasdaq listing compliance risk given low market cap and cash position

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001108205-26-000059
Document: cris-20260512.htm0001108205-26-000059
Document: 0001108205-26-000059-index-headers.html0001108205-26-000059
Document: 0001108205-26-000059-index.html0001108205-26-000059
Document: 0001108205-26-000059.txt0001108205-26-000059
8-K Data (Synthetic)0001108205-26-000059

Track record

18 reports on CRIS

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +82.45% at T+60 after the May 22, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.4200 Now $0.4400 +4.76% settles Nov 17
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.6000 Now $0.4400 −26.67% settles Nov 17
  3. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.5010 Now $0.4400 −12.18% settles Nov 17
  4. Nov 13, 20263d ago S-3 Bearish 7/10 Entry $0.6000 Now $0.4400 +26.67% settles Nov 17
  5. Nov 13, 20263d ago 8-K Neutral 4/10 Entry $0.4450 Now $0.4400 −1.12% settles Nov 17
  6. Nov 12, 20264d ago Press Release Bearish 6/10 Entry $0.4450 to $0.4358 Now $0.4400 +1.12% ▲ +2.07% +0.16% vs SPY
  7. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $0.6530 to $0.5915 Now $0.4400 −32.62% ▼ −9.42% −10.74% vs SPY
  8. Nov 6, 202610d ago 8-K Bearish 7/10 Entry $0.6976 to $0.6530 Now $0.4400 +36.93% ▲ +6.39% +6.03% vs SPY
  9. Nov 2, 202614d ago DEF 14A Neutral 4/10 Entry $0.6610 to $0.7139 Now $0.4400 −33.43% ▲ +8.00% +7.70% vs SPY
  10. Oct 19, 202628d ago 8-K Bearish 6/10 Entry $0.3996 to $0.3920 Now $0.4400 −10.11% ▲ +1.90% +2.43% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026